Last reviewed · How we verify
NCT07217431
Access BNP Clinical Performance Evaluation: Testing and Clinical Concordance Study
trial testing BNP in Heart Failure in 1,361 participants. Completed in 25 March 2025.
25 March 2025
Quick facts
| Lead sponsor | Beckman Coulter, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,361 |
| Start date | 10 October 2024 |
| Primary completion | 25 March 2025 |
| Estimated completion | 25 March 2025 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- BNP — full drug profile →
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Beckman Coulter, Inc.
Who can join
22 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal is to establish clinical performance of a BNP assay on the intended use population and establish clinical concordance on a separate device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07217431
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BNP
Trials testing the same drug.
- NCT06624293 — Access BNP Clinical Enrollment Study · completed
- NCT07013344 — Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease · recruiting
- NCT03738878 — Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 · Phase 4 · terminated
- NCT02668536 — A Sunscreen Based on Bioadhesive Nanoparticles · Phase 1 · completed
- NCT02041663 — Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis · NA · completed
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Beckman Coulter, Inc. trials
Trials by the same sponsor.
- NCT06624293 — Access BNP Clinical Enrollment Study · completed
- NCT06379061 — Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts · completed
- NCT06289868 — Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23) · completed
- NCT06257628 — MACE CDS Software Master Enrollment Protocol · withdrawn
- NCT05819762 — Evaluation of ClearLLab LS Screening Panel · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07217431 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beckman Coulter, Inc.
- Last refreshed: 16 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07217431.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing